醫藥和生物技術領域的選擇權和評估合約：2019-2026 年

本報告揭示了製藥和生物技術公司如何利用選擇權和評估協議來確保未來的權利、評估商業機會以及管理早期合作風險。

本報告提供了全球生命科學產業 1419 份選擇權和評估合約的全面資訊。

基於選擇權的合作關係允許公司在正式達成更廣泛的許可、開發或收購交易之前，評估資產、技術和發展機會。這種合作模式為潛在合作夥伴提供明確界定的未來權利，同時也使原權利持有者能夠在評估期間獲得資金、專業知識或示範機會。

本報告探討了這些交易在製藥和生物技術領域的合作中是如何被利用的，哪些公司最活躍，交易集中在哪些地區，以及可以從披露的財務條款和公開的合約文件中檢驗什麼。

本報告不僅列舉了具體的合約範例，還幫助讀者了解評估的內容、選擇權的結構、觸發未來合夥權利的條件、貨幣對價的分階段支付方式，以及類似協議的實際談判方式。

本報告為參與評估和談判基於期權的合作關係的業務發展、許可、研究和評估、公司戰略、研發戰略、法律和交易部門提供實用資訊和基準材料。

了解選擇權和估值合約的趨勢

本報告分析了2019年至2026年選擇權和估價合約的發展趨勢，內容包括：

• 選擇權和評估合約的年度趨勢
• 合作關係建立時的發展階段
• 產業部門
• 治療區域
• 技術類型
• 最積極簽訂選擇權和評估合約的公司
• 根據公開披露金額簽訂的主要合約
• 利用期權進行合作的戰略原因
• 選擇權和評估策略的變化
• 本報告深入分析了哪些領域的公司利用期權結構，哪些技術和治療領域吸引關注，以及哪些組織最積極地推廣這種分階段合作模式。
• 了解選擇權和評估合約的結構
• 選擇權和估值協議的形式多種多樣，但通常情況下，它們會賦予一方某些權利來評估特定的商業機會並進行交易。

本報告提供以下資訊，幫助使用者探索以下領域：

• 評估權範圍
• 選擇權權利及其行使方式
• 評估期
• 評估期內的獨家性
• 研發職責
• 智慧財產權所有權和進入許可權
• 關於資訊和資料的權利
• 行使選擇權的條件
• 未來許可或開發權
• 負責開發和商業化
• 期權費和其他付款
• 里程碑和其他財務條款（如已公開披露）
• 合約期限和終止條款
• 這些例子為確定在基於選擇權的合作關係中應包含多少柔軟性、排他性和未來承諾提供了寶貴的見解。
• 期權和估值合約的財務條款基準分析
• 本報告提供了與個別選擇權和估值協議相關的已揭露財務資訊。

根據合約詳情，可以查看以下項目。

• 與評估相關的付款
• 選擇權費
• 預付款
• 研究經費
• 行使選擇權時支付款項
• 開發和監管里程碑
• 商業化里程碑
• 忠誠條款
• 股票投資
• 其他已公開揭露的財務承諾
• 主要合約按其公開披露的合約價值排序，使可以識別重要的領先並詳細審查其合約結構。
• 這樣，就可以利用基於實際合約的資訊進行合約準備、內部基準測試和談判。
• 找出積極參與選擇權和評估合約的公司。
• 本報告列出了最積極參與期權和評估協議的前25 家公司，能夠準確地找出那些反覆利用分層合作結構來獲取外部創新的公司。

目錄

執行摘要

第1章 引言

第2章 選擇權交易與估價交易的趨勢

• 選擇權和評估合約的定義
• 選擇權和估值合約的發展趨勢
  • 年度期權和評估合約
  • 每個開發階段的選擇權和評估合約
  • 行業特定選擇權和評估合約
  • 依治療區域分類的選擇和評估合約
  • 依技術類型分類的選擇權和評估合約
  • 最活躍的公司特定期權和評估合約
• 簽訂選擇權/評估合作協議的原因
• 選擇權和評估合約的未來

第3章 選擇權和估價合約的架構：概述

• 期權和估值合約的結構

第4章 主要選擇權和評估協議

• 依合約金額分類的主要選擇權和評估合約

第5章 最積極簽訂選擇權和評估協議的25家公司

• 最積極簽訂選擇權和評估協議的前25 家公司

第6章 選擇權和評估合約目錄（含合約文件）

• 可選的評估契約，允許對合約進行審查。
• 合約目錄
• 交易目錄：依公司
• 交易目錄：依治療領域
• 交易目錄：依技術類型
• 關於生物製藥研究
• Current Partnering
• Current Agreements
• 理想合作夥伴近期報告標題

Understand how pharmaceutical and biotechnology companies use option and evaluation agreements to secure future rights, assess opportunities and manage early-stage partnering risk.

Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides comprehensive intelligence on 1,419 option and evaluation deals across the global life sciences industry.

Option-based partnerships allow companies to evaluate an asset, technology or development opportunity before committing to a broader licensing, development or acquisition transaction. They can provide the prospective partner with defined future rights while enabling the originating company to access funding, expertise or validation during the evaluation period.

The report examines how these transactions are being used across pharmaceutical and biotechnology partnering, which companies are most active, where dealmaking is concentrated and what can be learned from disclosed financial terms and publicly available contract documents.

Rather than simply identifying transactions, the report helps users understand what is being evaluated, how option rights are structured, what triggers future partnering rights, how financial consideration is staged and how comparable agreements have been negotiated in practice.

It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, legal and transaction teams evaluating or negotiating option-based partnerships.

Understand the option and evaluation deal landscape

The report analyzes option and evaluation dealmaking from 2019 to 2026, including:

• Trends in option and evaluation dealmaking by year
• Phase of development at the time of partnering
• Industry sector
• Therapy area
• Technology type
• Most active option and evaluation dealmakers
• Leading deals by disclosed value
• Strategic reasons for entering option-based partnerships
• How option and evaluation strategies are evolving
• This provides insight into where companies are using option structures, which technologies and therapeutic areas are attracting activity and which organizations are most actively pursuing this form of staged partnering.
• Understand how option and evaluation agreements are structured
• Option and evaluation agreements can take many forms, but typically provide one party with defined rights to evaluate an opportunity and potentially enter a subsequent transaction.

The report provides intelligence to help users examine areas including:

• Scope of evaluation rights
• Option rights and exercise mechanisms
• Evaluation periods
• Exclusivity during evaluation
• Research and development responsibilities
• Intellectual property ownership and access
• Information and data rights
• Option exercise triggers
• Future licensing or development rights
• Development and commercialization responsibilities
• Option fees and other payments
• Milestones and other financial terms where disclosed
• Term and termination provisions
• These real-world examples provide useful reference points when deciding how much flexibility, exclusivity and future commitment should be incorporated into an option-based partnership.
• Benchmark option and evaluation deal financials
• The report provides access to disclosed financial information associated with individual option and evaluation agreements.

Depending on the transaction, users can investigate elements including:

• Evaluation payments
• Option fees
• Upfront payments
• Research funding
• Option exercise payments
• Development and regulatory milestones
• Commercial milestones
• Royalty arrangements
• Equity investment
• Other financial commitments where disclosed
• Leading transactions are also ranked by disclosed deal value, enabling users to identify significant precedent deals and investigate their underlying structures.
• This provides evidence from real-world transactions to support deal preparation, internal benchmarking and negotiation.
• Identify active option and evaluation dealmakers
• The report profiles the Top 25 most active option and evaluation dealmakers, helping users identify companies repeatedly using staged partnering structures to access external innovation.

Transaction histories can help users understand:

• Which companies regularly enter option-based agreements
• Technologies and therapeutic areas attracting their interest
• Development stages at which companies are prepared to engage
• Potential partners for assets or technologies
• Previous transactions providing relevant precedents
• This makes the report particularly useful for business development, search and evaluation and competitive intelligence teams seeking organizations with a demonstrated appetite for emerging opportunities.
• Learn from real-world option and evaluation contracts
• Where publicly available, the report provides access to underlying option and evaluation contract documents.

These agreements can reveal significantly more than headline announcements, allowing users to examine how companies have documented provisions relating to:

• Evaluation rights and periods
• Option grant and exercise
• Exclusivity
• Intellectual property
• Development responsibilities
• Information and diligence obligations
• Option fees and financial consideration
• Future licensing rights
• Milestones and royalties
• Termination and expiry
• For teams preparing an option-based transaction, access to real agreement language provides valuable insight into how comparable provisions have been structured in practice.
• Comprehensive option and evaluation deal directory
• The report includes a comprehensive directory of 1,419 option and evaluation deals, enabling users to identify transactions relevant to their own assets, technologies and partnering objectives.

Deals can be reviewed by:

• Company
• Therapy area
• Technology type
• Contract availability
• Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
• Who should use this report?
• Business Development and Licensing teams
• Identify comparable option agreements, prospective partners and relevant structures when preparing staged partnering strategies.
• Search and Evaluation teams
• Understand which companies are using options to secure access to emerging assets and technologies and investigate their previous partnering activity.
• Biotechnology Companies Seeking Partners
• Identify organizations prepared to engage with technologies and assets before a full licensing commitment is appropriate.
• Corporate and R&D Strategy teams
• Understand how companies use staged investment and evaluation rights to access external innovation while managing development risk.
• Legal and Transaction teams
• Review real-world agreement structures and publicly available contract language covering option rights, evaluation periods, exclusivity and future licensing provisions.
• Competitive Intelligence teams
• Track option activity to understand where companies are securing early access to technologies, assets and emerging areas of innovation.
• Turn market-wide intelligence into company-specific insight
• For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
• The briefing applies the underlying option and evaluation deal intelligence to the customer's own assets, technologies or partnering objectives.
• Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, option structures, financial benchmarks, contract insights and other intelligence selected specifically for the client's situation.
• Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in option and evaluation dealmaking

• 2.1. Introduction
• 2.2. Definition of option and evaluation deal
• 2.3. Trends in option and evaluation deals
  • 2.3.1. Option and evaluation dealmaking by year
  • 2.3.2. Option and evaluation dealmaking by phase of development
  • 2.3.3. Option and evaluation dealmaking by industry sector
  • 2.3.4. Option and evaluation dealmaking by therapy area
  • 2.3.5. Option and evaluation dealmaking by technology type
  • 2.3.6. Option and evaluation dealmaking by most active company
• 2.4. Reasons for entering into option and evaluation partnering deals
• 2.5. The future of option and evaluation deals

Chapter 3 - Overview of option and evaluation deal structure

• 3.1. Introduction
• 3.2. Option and evaluation agreement structure

Chapter 4 - Leading option and evaluation deals

• 4.1. Introduction
• 4.2. Top option and evaluation deals by value

Chapter 5 - Top 25 most active option and evaluation dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active option and evaluation dealmakers

Chapter 6 - option and evaluation deals including contracts directory

• 6.1. Introduction
• 6.2. Option and evaluation deals with contracts
• Deal directory
• Deal directory - option and evaluation dealmaking by companies A-Z
• Deal directory - option and evaluation dealmaking by therapy area
• Deal directory - option and evaluation dealmaking by technology type
• About Biopharma Research
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of option and evaluation
• Figure 2: Trends in option and evaluation deal announcements
• Figure 3: Option and evaluation deals signed at each phase of development
• Figure 4: Option and evaluation deals by industry sector
• Figure 5: Option and evaluation deals by therapy area
• Figure 6: Option and evaluation deals by technology type
• Figure 7: Top 25 most active option and evaluation dealmakers
• Figure 8: Top option and evaluation deals by value
• Figure 9: Most active option and evaluation dealmakers